Are biopharmaceutical budget caps good public policy?
Year of publication: |
2016
|
---|---|
Authors: | Goldman, Dana P. ; Lakdawalla, Darius ; Baumgardner, James R. ; Linthicum, Mark T. |
Published in: |
The Economists' voice. - Berlin : De Gruyter, ISSN 1553-3832, ZDB-ID 2162320-X. - Vol. 13.2016, 1, p. 27-42
|
Subject: | cost-effectiveness | health economics | pharmaceuticals | Arzneimittel | Pharmaceuticals | Pharmaindustrie | Pharmaceutical industry | Gesundheitsökonomik | Health economics | Gesundheitspolitik | Health policy | Gesundheitskosten | Health care costs | EU-Staaten | EU countries | Kosten-Wirksamkeits-Analyse | Cost-effectiveness analysis | Öffentlicher Haushalt | Public budget |
-
Orphan drugs policies : a suitable case for treatment ; editorial
Drummond, Michael F., (2014)
-
Jin, Huajie, (2019)
-
Nguyen Cuc Thi Thu, (2019)
- More ...
-
Can oral nutritional supplements improve medicare patient outcomes in the hospital?
Lakdawalla, Darius, (2014)
-
HIV breakthroughs and risky sexual behavior
Lakdawalla, Darius, (2006)
-
Food prices and the dynamics of body weight
Goldman, Dana P., (2009)
- More ...